JP5818977B2 - 細胞膜透過性の線維芽細胞増殖因子の医療用途 - Google Patents

細胞膜透過性の線維芽細胞増殖因子の医療用途 Download PDF

Info

Publication number
JP5818977B2
JP5818977B2 JP2014510567A JP2014510567A JP5818977B2 JP 5818977 B2 JP5818977 B2 JP 5818977B2 JP 2014510567 A JP2014510567 A JP 2014510567A JP 2014510567 A JP2014510567 A JP 2014510567A JP 5818977 B2 JP5818977 B2 JP 5818977B2
Authority
JP
Japan
Prior art keywords
amino acid
fgf1
acid sequence
cpp
chimeric protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014510567A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2014084027A1 (ja
Inventor
文明 中山
文明 中山
禎子 梅田
禎子 梅田
武嗣 安田
武嗣 安田
真由美 藤田
真由美 藤田
今井　高志
高志 今井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes For Quantum Science and Technology
Original Assignee
National Institutes For Quantum Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes For Quantum Science and Technology filed Critical National Institutes For Quantum Science and Technology
Priority to JP2014510567A priority Critical patent/JP5818977B2/ja
Application granted granted Critical
Publication of JP5818977B2 publication Critical patent/JP5818977B2/ja
Publication of JPWO2014084027A1 publication Critical patent/JPWO2014084027A1/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
JP2014510567A 2012-11-28 2013-11-11 細胞膜透過性の線維芽細胞増殖因子の医療用途 Expired - Fee Related JP5818977B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014510567A JP5818977B2 (ja) 2012-11-28 2013-11-11 細胞膜透過性の線維芽細胞増殖因子の医療用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012259816 2012-11-28
JP2012259816 2012-11-28
JP2014510567A JP5818977B2 (ja) 2012-11-28 2013-11-11 細胞膜透過性の線維芽細胞増殖因子の医療用途
PCT/JP2013/080382 WO2014084027A1 (ja) 2012-11-28 2013-11-11 細胞膜透過性の線維芽細胞増殖因子の医療用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015191288A Division JP6183757B2 (ja) 2012-11-28 2015-09-29 細胞膜透過性の線維芽細胞増殖因子の医療用途

Publications (2)

Publication Number Publication Date
JP5818977B2 true JP5818977B2 (ja) 2015-11-18
JPWO2014084027A1 JPWO2014084027A1 (ja) 2017-01-05

Family

ID=50827673

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014510567A Expired - Fee Related JP5818977B2 (ja) 2012-11-28 2013-11-11 細胞膜透過性の線維芽細胞増殖因子の医療用途
JP2015191288A Expired - Fee Related JP6183757B2 (ja) 2012-11-28 2015-09-29 細胞膜透過性の線維芽細胞増殖因子の医療用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015191288A Expired - Fee Related JP6183757B2 (ja) 2012-11-28 2015-09-29 細胞膜透過性の線維芽細胞増殖因子の医療用途

Country Status (3)

Country Link
US (1) US20150299280A1 (https=)
JP (2) JP5818977B2 (https=)
WO (1) WO2014084027A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114874990A (zh) * 2021-02-05 2022-08-09 中国科学院苏州纳米技术与纳米仿生研究所 一种功能化外泌体及其制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6675150B2 (ja) * 2015-04-06 2020-04-01 公立大学法人大阪 サイトグロビン発現増強剤
US10385113B2 (en) 2016-03-30 2019-08-20 The Board Of Trustees Of The University Of Arkansas Engineered FGF compositions and methods of use thereof
US11267855B2 (en) 2018-03-16 2022-03-08 The Board Of Trustees Of The University Of Arkansas Engineered FGF1 and FGF2 compositions and methods of use thereof
CN114829582A (zh) * 2019-12-16 2022-07-29 Jsr株式会社 类器官的制造方法
CZ309550B6 (cs) * 2021-06-15 2023-04-05 Enantis s.r.o Termostabilní polypeptid na bázi FGF18 a jeho použití

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6013060274; ＮＡＫＡＹＡＭＡ　Ｆ．ｅｔ　ａｌ．: 'Ｆｉｂｒｏｂｌａｓｔ　ｇｒｏｗｔｈ　ｆａｃｔｏｒ-１２　（ＦＧＦ１２）　ｔｒａｎｓｌｏｃａｔｉｏｎ　ｉｎｔｏ　ｉｎｔｅｓｔｉｎａｌ　ｅｐｉｔｈｅｌｉａｌ　ｃｅｌｌｓ　ｉｓ　ｄｅｐｅｎｄｅｎｔ　ｏｎ　ａ' Ｊ．Ｂｉｏｌ．Ｃｈｅｍ．，２０１１　Ｊｕｌ　２２，２８６（２９），ｐ．２５８２３-３４ *
JPN6013060277; 中山　文明，他６名: 'ＦＧＦ１２の小腸に対する放射線防護効果について' 日本放射線影響学会大会講演要旨集，２０１１　Ｎｏｖ　１，５４，ｐ．１６２，ＰＥ-２ *
JPN6013060278; ＨＡＧＩＷＡＲＡ　Ａ．ｅｔ　ａｌ．: 'Ｃｏｍｐａｒｉｓｏｎ　ｏｆ　ｅｘｐｒｅｓｓｉｏｎ　ｐｒｏｆｉｌｅｓ　ｏｆ　ｓｅｖｅｒａｌ　ｆｉｂｒｏｂｌａｓｔ　ｇｒｏｗｔｈ　ｆａｃｔｏｒ　ｒｅｃｅｐｔｏｒｓ　ｉｎ　ｔｈｅ　ｍｏｕｓｅ　ｊｅｊｕｎｕｍ' Ｒａｄｉａｔ．Ｒｅｓ．，２００９　Ｊｕｌ，１７２（１），ｐ．５８-６５（ａｂｓｔｒａｃｔ），Ｄａｔａ　Ｒｅｖｉｓｅｄ　２００９　Ａｕｇ　３，ＰｕｂＭｅｄ［ｏｎｌｉｎｅ］ , Ｎａｔｉｏｎａｌ　Ｃｅｎｔｅｒ　ｆｏｒ　Ｂｉｏｔｅｃｈｎｏｌｏｇｙ　Ｉｎｆｏｒｍａｔｉｏｎ，　Ｕ&#xFF0 *
JPN6013060279; ＮＡＫＡＹＡＭＡ　Ｆ．ｅｔ　ａｌ．: 'Ｅｖａｌｕａｔｉｏｎ　ｏｆ　ｒａｄｉａｔｉｏｎ-ｉｎｄｕｃｅｄ　ｈａｉｒ　ｆｏｌｌｉｃｌｅ　ａｐｏｐｔｏｓｉｓ　ｉｎ　ｍｉｃｅ　ａｎｄ　ｔｈｅ　ｐｒｅｖｅｎｔｉｖｅ　ｅｆｆｅｃｔｓ　ｏｆ　ｆｉｂｒｏｂ' Ｅｘｐ．Ｄｅｒｍａｔｏｌ．，２００９　Ｏｃｔ，１８（１０），ｐ．８８９-９２ *
JPN6013060280; ＣＨＥＮ　Ｇ．ｅｔ　ａｌ．: 'Ｔｈｅｒｍａｌ　ｓｔａｂｉｌｉｔｙ　ｏｆ　ｆｉｂｒｏｂｌａｓｔ　ｇｒｏｗｔｈ　ｆａｃｔｏｒ　ｐｒｏｔｅｉｎ　ｉｓ　ａ　ｄｅｔｅｒｍｉｎａｎｔ　ｆａｃｔｏｒ　ｉｎ　ｒｅｇｕｌａｔｉｎｇ　ｓｅｌｆ-ｒｅｎ' Ｓｔｅｍ　Ｃｅｌｌｓ，２０１２　Ａｐｒ，３０（４），ｐ．６２３-３０ *
JPN6013060281; ＬＩＵ　Ｚ．ｅｔ　ａｌ．: 'Ｉｄｅｎｔｉｆｉｃａｔｉｏｎ　ｏｆ　ａ　ｆｉｂｒｏｂｌａｓｔ　ｇｒｏｗｔｈ　ｆａｃｔｏｒ　ｒｅｃｅｐｔｏｒ　１　ｓｐｌｉｃｅ　ｖａｒｉａｎｔ　ｔｈａｔ　ｉｎｈｉｂｉｔｓ　ｐａｎｃｒｅａｔｉｃ　ｃａｎｃ' Ｃａｎｃｅｒ　Ｒｅｓ．，２００７　Ｍａｒ　１５，６７（６），ｐ．２７１２-９ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114874990A (zh) * 2021-02-05 2022-08-09 中国科学院苏州纳米技术与纳米仿生研究所 一种功能化外泌体及其制备方法和应用

Also Published As

Publication number Publication date
WO2014084027A1 (ja) 2014-06-05
JP2016029071A (ja) 2016-03-03
US20150299280A1 (en) 2015-10-22
JPWO2014084027A1 (ja) 2017-01-05
JP6183757B2 (ja) 2017-08-23

Similar Documents

Publication Publication Date Title
JP7339372B2 (ja) 代謝障害を処置するための融合タンパク質
JP6183757B2 (ja) 細胞膜透過性の線維芽細胞増殖因子の医療用途
JP6110304B2 (ja) Ｆｇｆ２１関連障害を処置する方法
US8324160B2 (en) Chimeric polypeptides and uses thereof
CN104147591B (zh) Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗各种疾病的应用
EP3004152B1 (en) Designed ankyrin repeat proteins binding to hepatocyte growth factor
JP5414078B2 (ja) 高機能化キメラ蛋白質を含有する細胞増殖促進用培地
JP2023025005A (ja) 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤
JP2021184727A (ja) 長時間作用型ｆｇｆ２１融合タンパク質およびそれを含む医薬組成物
CN109535243B (zh) 人肝细胞生长因子突变体及其应用
KR20120034927A (ko) 피부투과성 인간 상피세포 성장인자 및 그 생산방법
EP3125921B1 (en) Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy
CN108440668A (zh) Fgf21与igf-1的融合蛋白及其应用
AU2016203988B2 (en) Protein to promote blood vessel growth and uses thereof
US20110092441A1 (en) Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component
JP4537206B2 (ja) 血管新生を阻害するｈａｒｐ因子のペプチドフラグメント
AU2008256550B2 (en) VEGF-D mutants and their use
JP6944875B2 (ja) Ｍｅｔ受容体アゴニストタンパク質
WO2025247922A1 (en) Use of the recombinant fibrinogen-like domain of angiopoietin-like 4 for treating sepsis capillary leak syndrome
Boettcher et al. Patent: Methods of Treating FGF21-Associated Disorders
HK40012348A (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
JP2016036322A (ja) 血管新生因子と結合するキメラタンパク質
CN107531802A (zh) 来自肝细胞生长因子/散射因子（hgf/sf）的kringle结构域的多聚体化合物

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150929

R150 Certificate of patent or registration of utility model

Ref document number: 5818977

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees